ZyVersa Therapeutics, Inc.
ZVSA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001859007
No open-market purchases or sales by ZyVersa Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding ZyVersa Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 6 | 1 | −5 |
| Shares | 66.1K | 7 | −66.1K (−100.0%) |
| Value | $44.7K | $1 | −$44.7K (−100.0%) |
New holders (1)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Guerra Advisors Inc | 7 | $1 | 0.00% |
Sold out (6)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| UBS Group AG | 39,280 | $26.6K |
| Geode Capital Management, LLC | 21,706 | $14.7K |
| Tower Research Capital LLC (TRC) | 4,525 | $3.06K |
| Citigroup Inc | 274 | $186 |
| SBI Securities Co., Ltd. | 151 | $102 |
| Bank of America Corp | 132 | $90 |